Search Clinical Trials
Completed
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (External Link)
A maximum of 30 subjects will participate in the treatment part of this study. Up to 180ml of blood is collected from patients to grow the T cells. The T …
Baylor Role:
Lead Sponsor
Completed
High-Risk Neuroblastoma Chemotherapy Without G-CSF (External Link)
Chemotherapy: CYCLE 1+2: Topotecan and cyclophosphamide Cycle 3+5: Cisplatin and Etoposide Cycle 4+6: Vincristine, Cyclophosphamide and Doxorubicin Stem cell collection: After the third cycle of chemotherapy, stem cells will be …
Baylor Role:
Lead Sponsor
Completed
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (External Link)
The subject will need to have a variety of tests, exams, or procedures to find out if s/he can be on the study. The subject will also require placement of …
Baylor Role:
Lead Sponsor
Completed
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A (External Link)
At first the subject will have 2 cycles of cancer drugs (Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide). The doctors call this combination of cancer drugs ABVE-PC for short. A cycle …
Baylor Role:
Lead Sponsor
Completed
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (External Link)
The following will be given as the conditioning regimen for the transplant: BUSULFAN: Busulfan (intravenous BUSULFEX) dosing will be as follows: patients <12 kg: 1.1 mg/kg/dose IV every 6 hours …
Baylor Role:
Lead Sponsor
Completed
Umbilical Cord Blood Transplant for Congenital Pediatric Disorders (External Link)
Patients will be examined to make sure that they meet the requirements of this study. There will be tests of the heart and of the lungs. X-rays will be taken …
Baylor Role:
Lead Sponsor
Completed
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma (External Link)
Induction Phase Overview The induction phase is approximately 15 weeks long. Chemotherapy is generally given every 3 weeks, each 3 week block is called a "cycle". During these 15 weeks …
Baylor Role:
Lead Sponsor
Completed
Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010) (External Link)
This is a Phase 1, open-label, dose-escalating study of karenitecin plus cyclophosphamide in the treatment of pediatric patients with refractory or recurrent solid tumors. All patients must have histologically documented …
Baylor Role:
Lead Sponsor
Completed
Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement (External Link)
Zoledronic Acid (Zometa), a new generation, highly potent bisphosphonate used to treat osteoporosis and hypercalcemia of malignancy, is widely used in adult malignancies with potential for bone metastasis such as …
Baylor Role:
Lead Sponsor
Completed
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients (External Link)
Large clinical trials have confirmed the value of systemic adjuvant therapy in decreasing the risk of recurrence and death in patients with early breast cancer. However, the need to identify …
Baylor Role:
Collaborator